Search
for
Sort by
Research 631–660 of 1000+
- Polycystic Ovary Syndrome: Conditions, Genetics and Current Cure
- Workup and Management of Polycystic Ovary Syndrome
- Minimal systemic exposure of a new topical triazole antifungal, efinaconazole 10% solution, in patients with severe onychomycosis following 28-day treatment
- Obstetric and Gynecologic Dermatology
- New onset of alopecia in a young woman with end-stage renal disease
- Hormone therapy in acne
- An Exclusive Review on Menstrual Problems
- Genotypes of Single-nucleotide polymorphisms on DENND1A in an association with polycystic ovary syndrome among Saudi Arabian females
- Unveiling Therapeutic Potential of Yoga Mitigating Oxidative Stress and Mitochondrial Dysfunction in PCOS: A Randomized Controlled Trial
- Paclitaxel/Platinum combination regimen and alopecia
- PCOS in Adolescents—Ongoing Riddles in Diagnosis and Treatment
- Effects of the prenatal and postnatal nurturing environment on the phenotype and gut microbiota of mice with polycystic ovary syndrome induced by prenatal androgen exposure: a cross-fostering study
- Effect of Vitamin D Supplementation on Ovulation Induction Among Women with Poly Cystic Ovary Syndrome
- P-424
- Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231
- Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management
- Treatment of hirsutism and acne in women with two combinations of cyproterone acetate and ethinylestradiol.
- Clinical and Biochemical Characteristics in PCOS Women With Menstrual Abnormalities.
- Shock: A possible presenting manifestation of autoimmune polyendocrine syndrome type II
- Virilisation in a young woman: A case demonstrating the importance of co-located mental and primary healthcare
- Homoeopathic Management of Alopecia Areata Associated with Hypothyroidism at Dr Batra's
- Homoeopathic Management of Alopecia Areata Associated with Hypothyroidism at Dr Batra's
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Analysis of Hirsutism as a Symptom of Ihtibās al-Tamth (Amenorrhea) and its Relation to Polycystic Ovary Syndrome.
- Female Pelvic Conditions: Polycystic Ovary Syndrome.
- WRIST PAIN IN A GYMNAST WITH PRIMARY AMENORRHEA
- Switching roles: the functional plasticity of adult tissue stem cells
- Protein Kinase C as a Therapeutic Target
- New insights into the role of Runx1 in epithelial stem cell biology and pathology